68 80

Cited 2 times in

Improved prognostic stratification using NCCN- and GELTAMO-international prognostic index in patients with diffuse large B-cell lymphoma

Authors
 Junshik Hong  ;  Seok Jin Kim  ;  Myung Hee Chang  ;  Jeong-A Kim  ;  Jae-Yong Kwak  ;  Jin Seok Kim  ;  Dok Hyun Yoon  ;  Won Sik Lee  ;  Young Rok Do  ;  Hye Jin Kang  ;  Hyeon-Seok Eom  ;  Yong Park  ;  Jong-Ho Won  ;  Yeung-Chul Mun  ;  Hyo Jung Kim  ;  Jung Hye Kwon  ;  Jee Hyun Kong  ;  Sung Yong Oh  ;  Sunah Lee  ;  Sung Hwa Bae  ;  Deok-Hwan Yang  ;  Hyun Jung Jun  ;  Ho Sup Lee  ;  Hwan Jung Yun  ;  Soon Il Lee  ;  Min Kyoung Kim  ;  Jun Ho Yi  ;  Jae Hoon Lee  ;  Won Seog Kim  ;  Cheolwon Suh 
Citation
 ONCOTARGET , Vol.8(54) : 92171-92182, 2017 
Journal Title
 ONCOTARGET 
Issue Date
2017
Keywords
diffuse large B-cell lymphoma ; international prognostic index ; non-hodgkin lymphoma ; overall survival ; prognosis
Abstract
The National Comprehensive Cancer Network (NCCN)-International Prognostic Index (IPI) and GELTAMO (Grupo Español de Linfomas/Trasplante Autólogo de Médula Ósea)-IPI were developed to enable better risk prediction of patients with diffuse large B-cell lymphoma (DLBCL). The present study compared the effectiveness of risk prediction between IPI, NCCN-IPI, and GELTAMO-IPI in patients with DLBCL particularly in terms of determining high-risk patients. Among 439 patients who were enrolled to a prospective DLBCL cohort treated with R-CHOP immunochemotherapy, risk groups were classified according to the three IPIs and the prognostic significance of individual IPI factors and IPI models were analyzed and compared. All three IPI effectively separated the analyzed patients into four risk groups according to overall survival (OS). Estimated 5-year OS of patients classified as high-risk according to the IPI was 45.7%, suggesting that the IPI is limited in the selection of patients who are expected to have a poor outcome. In contrast, the 5-year OS of patients stratified as high-risk according to NCCN- and GELTAMO-IPI was 31.4% and 21.9%, respectively. The results indicate that NCCN- and GELTAMO-IPI are better than the IPI in predicting patients with poor prognosis, suggesting the superiority of enhanced, next-generation IPIs for DLBCL.
Files in This Item:
T201705268.pdf Download
DOI
10.18632/oncotarget.20988
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
Yonsei Authors
Kim, Jin Seok(김진석) ORCID logo https://orcid.org/0000-0001-8986-8436
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/161598
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse